Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial. The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across 12 months. Patients were randomized in a 1:1 fashion, to receive either oral torsemide or oral furosemide. Results from the QoL suggest that among patients with HF, a routine strategy of prescribing torsemide versus furosemide did not meaningfully impact patient symptoms or quality of life over 12-month follow-up.
Interview Questions:
1. What is the background of this study?
2. How do torsemide and furosemide differ in terms of their mechanisms of action?
3. What was the rationale behind this QoL study?
4. What is the study design and patient population?
5. What data are you presenting at HFA 23?
6. Based on the results, what are the key messages?
7. What are the remaining unanswered questions regarding the choice of loop diuretic?
Recorded on-site at HFA 23, in Prague.
Visit Radcliffe Cardiology:
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook:
Follow us on Twitter:
Музыка
Фильмы
ТВ Шоу
Категории видео
